Staines-Upon-Thames, England (ots/PRNewswire) - EUR50,000 award goes to Rotherham NHS Foundation Trust Department of Haematology Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today announced the inaugural recipient of its Advancing Extracorporeal Photopheresis (ECP) Immunomodulation Investigator Award. The winning entry was submitted by ...
Chicago (ots/PRNewswire) - Oral session #12 Adults with obesity treated with semaglutide 0.4 mg administered once-daily via subcutaneous injections lost up to 13.8% of their body weight after 52 weeks in a phase 2 trial, significantly more than those treated with placebo who lost 2.3% of their body weight.[1] An ...
Zurich, SWITZERLAND (ots) - Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis Sequana Medical AG ("Sequana Medical"), a commercial stage medical device company and an innovator in the management of ...
Stockholm (ots/PRNewswire) - OxThera AB, a Stockholm-based privately-held biopharmaceutical company with a product in late stage clinical development focusing on Primary hyperoxaluria (PH), announces the randomization of the first patient into its phase III study, EPHEX, with Oxabact. Study OC5-DB-02 (EPHEX) is a ...
Rehovot, Israel (ots/PRNewswire) - Israel becomes the first country in the world to grant medical device approval for a medical cannabis vaporizer Kanabo Research, a Tel-Aviv-based medical cannabis R&D company, is pleased to announce that the Israeli Ministry of Health has granted initial approval as a medical ...
Ganterschwil (ots) - The Board of Directors of Berlinger Special AG has resolved that the company will cease production of its doping control kits in the medium term. To avoid jeopardizing current anti-doping activities, the company will continue to supply its present customers at their request for a transitional ...
Amsterdam (ots/PRNewswire) - Debuted at ECR 2018, the newest addition to Philips' digital MR solutions portfolio provides breakthrough in speed, improved patient experience and clinical confidence Royal Philips (http://www.philips.com/) (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced ...
Hitachi Medical Systems Europe Holding AG
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K./U.S. based media - First oral short-course treatment for highly active relapsing multiple sclerosis (RMS) now approved in Argentina - Mavenclad has shown sustained clinical efficacy for up to 4 years with a maximum of 20 days of oral treatment over 2 years Merck, a leading science and technology company, today ...
Amsterdam (ots/PRNewswire) - Arc Medical Design Limited, a subsidiary of Norgine B.V., today announced that the High Court of Justice England and Wales, Patents Court ruled that ENDOCUFF® and ENDOCUFF VISION® UK national and UK(EP) patents (as amended) are valid and infringed by Cantel's AmplifEYE® endoscopic ...
Haifa, Israel and Miami (ots/PRNewswire) - INSIGHTEC®, a commercial-stage medical technology company revolutionizing surgery with incisionless MR-guided focused ultrasound (MRgFUS) announced today that the Neuravive focused ultrasound treatment will be a covered service for essential tremor patients in Israel. The ...
Takeda Pharmaceutical Company Limited
Osaka, Japan (ots/PRNewswire) - New clinical study also provides data for Entyvio® in inducing complete mucosal healing and endoscopic remission, particularly in bio-naïve patients Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") today announced new real-world data evaluating the comparative ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced results from the Phase III JAVELIN Lung 200 trial comparing avelumab* to docetaxel in patients with unresectable, recurrent or metastatic non-small cell lung cancer (NSCLC) whose ...
Lausanne (ots) - Debiopharm Group (TM) announces an investment in antibiotic development with the acquisition of a minority stake in ABAC Therapeutics Inc. This investment was made through the Debiopharm Innovation Fund, its strategic investment fund, and illustrates the synergy between the group companies in the ...
Bagsværd, Denmark (ots/PRNewswire) - Results from the SUSTAIN 7 trial, which investigated the efficacy and safety of 0.5 mg semaglutide compared with 0.75 mg dulaglutide and 1.0 mg semaglutide compared with 1.5 mg dulaglutide, when added to metformin, have been published in The Lancet Diabetes & Endocrinology.[1] ...
Haifa, Israel and Miami (ots/PRNewswire) - INSIGHTEC, a commercial-stage medical technology company revolutionizing surgery with incisionless MRI-guided focused ultrasound (MRgFUS) announced today the closing of a $150 million Series E private equity investment round. Koch Disruptive Technologies (KDT), a subsidiary of Koch Industries, focused on finding and funding innovative and emerging companies, led the round with a ...
Sunnyvale, California (ots/PRNewswire) - CyberKnife Frameless Radiosurgery Offers a Precise and Non-Invasive Technique with Clinical Outcomes Similar to Gamma Knife Frame-Based Invasive Radiosurgery Accuray Incorporated (NASDAQ: ARAY) announced today that data from a study of 138 patients with trigeminal neuralgia (TN) showed stereotactic radiosurgery (SRS) delivered ...
Loures, Portugal (ots/PRNewswire) - Hovione announced that a new MG2 Tekna Precision Capsule filling unit is now online in its Portugal facilities. This investment reinforces Hovione's Services portfolio in inhalation product development capabilities (http://www.hovione.com/products-and-services/contract-manufacturing-services/drug-product/innovation-and-expertise), which include proprietary particle engineering ...
Almere, The Netherlands (ots/PRNewswire) - Emotional Brain is pleased to announce the publication of positive phase 2B results in the authoritative Journal of Sexual Medicine (http://www.jsm.jsexmed.org/article/S1743-6095(17)31851-9/fulltext). Lybrido and Lybridos were successfully tested in 497 women with Female ...
Brussels (ots/PRNewswire) - - European Medicines Agency (EMA) has approved label change for UCB's CIMZIA® (certolizumab pegol), making it the first anti-TNF for potential use in women with chronic rheumatic disease, during both pregnancy and breastfeeding - Data submitted to regulatory authorities included ...
Hombrechtikon Systems Engineering AG
Darmstadt, Germany and New York (ots/PRNewswire) - - Second Breakthrough Therapy Designation for avelumab in hard-to-treat cancer - Renal cell carcinoma, the most common form of kidney cancer, has a poor prognosis in advanced stage[1],[2] - Javelin Renal clinical development program is ongoing, including Phase III ...
Odense, Denmark, and Smiths Falls, Ontario (ots/PRNewswire) - Further to a December 5th press release announcing plans to establish a 40,000 m2 facility in the Danish city of Odense, Spectrum Cannabis Denmark has been issued a cannabis production licence by Laegemiddelstyrelsen, Denmark's Medicines Agency. Danish Health Minister, Ellen Trane Nørbye, announced the news ...
European Society for Medical Oncology (ESMO)
Lugano (ots) - ESMO, the leading professional organisation for medical oncology, published a position paper on supportive and palliative care, calling attention to the evolving and growing gap between the needs of cancer patients and the actual provision of patient-centred care. "New studies show that there may be a gap between what doctors think is important for patients, and what patients really need. With this position ...
Munich (ots/PRNewswire) - For EU media only - not for US journalists - Hokusai-VTE CANCER study is a phase 3b, prospective, randomised, open-label, blind end-point (PROBE) study evaluating edoxaban versus low molecular weight heparin (LMWH) dalteparin in venous thromboembolism (VTE) associated with primarily active ...
Bagsværd, Denmark (ots/PRNewswire) - - Results published in Diabetes, Obesity and Metabolism Newly published data from real-world European clinical practice has shown that Xultophy® (insulin degludec/liraglutide) significantly reduced blood sugar levels in people with type 2 diabetes after six months.[1] The study ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K./U.S. based media - First treatment in relapsing-remitting multiple sclerosis (RRMS) to show sustained clinical efficacy for up to 4 years with a maximum of 20 days of oral treatment over 2 years - Updated registration follows recent approval of Mavenclad in Europe and Canada Merck, a leading science and ...
Abu Dhabi, Uae (ots/PRNewswire) - In people with type 2 diabetes who fast during Ramadan, Ryzodeg® (insulin degludec/insulin aspart) reduced the overall rate of low blood sugar (hypoglycaemia) including severe episodes by 62% and the rate of nocturnal hypoglycaemia by 74% versus biphasic insulin aspart 30 (BIAsp 30 ...
Abu Dhabi, Uae (ots/PRNewswire) - People with either type 1 or type 2 diabetes treated with Tresiba® had fewer episodes of low blood sugar (hypoglycaemia) compared with people on insulin glargine U100 regardless of whether they had achieved blood sugar targets.[1] These new post-hoc analyses from the SWITCH 1 and 2 trials were presented at the International Diabetes Federation (IDF) Annual Congress in Abu Dhabi ...